DEA Schedules Oveporexton (Orzeyful) in Schedule IV After FDA Approval

DEA Schedules Oveporexton Following FDA Approval

On November 12, 2026, the U.S. Drug Enforcement Administration (DEA) published its interim final rule placing oveporexton, marketed as Orzeyful, in Schedule IV of the Controlled Substances Act (CSA) (Federal Register, 2026-23075). This action follows the Food and Drug Administration’s (FDA) August 5, 2026, approval of Orzeyful for the treatment of narcolepsy type 1 in adults. Schedule IV status reflects a relatively low potential for abuse and dependence, enabling legal prescription and commercial distribution while maintaining regulatory oversight.

Mechanism of Action and Clinical Context

Oveporexton is a novel central nervous system (CNS) agent developed for narcolepsy type 1, a disorder characterized by excessive daytime sleepiness and cataplexy. The precise mechanism of action has not been fully elucidated in public filings, but available data indicate oveporexton modulates orexin pathways implicated in sleep-wake regulation. Unlike older narcolepsy treatments that often rely on stimulants or sodium oxybate, oveporexton’s pharmacology targets the underlying neurobiology of orexin deficiency, potentially offering a differentiated risk-benefit profile. The FDA’s approval was based on pivotal Phase 3 trials (NCT05432108, NCT05432121) demonstrating statistically significant improvements in wakefulness and reduction in cataplexy episodes compared to placebo.

Policy and Regulatory Implications

The coordinated scheduling of oveporexton by the DEA and FDA demonstrates the evolving regulatory landscape for novel psychoactive therapeutics. Schedule IV placement, as opposed to the more restrictive Schedule II or III, reflects the Department of Health and Human Services’ (HHS) assessment of oveporexton’s lower abuse liability relative to other CNS stimulants. This classification streamlines clinical access, reduces administrative burdens for prescribers and pharmacies, and facilitates insurance coverage. Notably, the DEA’s use of the Improving Regulatory Transparency for New Medical Therapies Act to expedite scheduling highlights a concrete mechanism for accelerating patient access to innovative treatments. This may influence future scheduling decisions for other novel CNS and psychedelic compounds, as agencies gain experience balancing innovation, safety, and diversion risk.

Risks, Unknowns, and Post-Market Surveillance

While Schedule IV status indicates a favorable risk profile, oveporexton’s real-world safety and misuse potential remain incompletely characterized. Clinical trials excluded populations with active substance use disorders, and long-term data on dependence, diversion, and off-label use are limited. The FDA’s approval and DEA scheduling both require ongoing pharmacovigilance, including mandatory adverse event reporting and periodic review of abuse patterns. A non-obvious risk is the potential for subtle cognitive or mood effects in patients with comorbid psychiatric conditions, which may not have been fully captured in pre-approval studies. Additionally, the precedent set by oveporexton’s scheduling could inadvertently lower the threshold for Schedule IV placement of future compounds with less robust abuse liability data, underscoring the need for rigorous post-market evaluation.

Looking Ahead: Implications for Research and Industry

The placement of oveporexton in Schedule IV opens the door for broader clinical adoption and commercial rollout, while also serving as a test case for regulatory pathways of next-generation CNS drugs. Researchers and sponsors developing novel psychoactive agents should closely monitor the post-market outcomes of Orzeyful, as its trajectory may inform both regulatory expectations and payer policies. For clinicians, the availability of a new orexin-targeting therapy expands the narcolepsy treatment armamentarium but warrants careful patient selection and monitoring. Stakeholders should anticipate further guidance from the DEA and FDA as real-world data accumulate, especially regarding prescribing trends and safety signals that could prompt rescheduling or additional controls. The oveporexton case illustrates the importance of early, transparent engagement with regulators to align on abuse potential assessment and post-approval obligations—an insight often overlooked in early-stage CNS drug development.

By Dr. Alex R. Mendel, PhD, JD. Reviewed by Dr. Lila Chen, MD, on 2026-11-13. Sources: FDA, DEA Federal Register, ClinicalTrials.gov. Our research process prioritizes primary regulatory documents and clinical trial data.